BerGenBio to present at AACR 2016

BerGenBio will present a poster entitled: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy.
Look for abstract #566 in poster section 26 to speak to our researchers about how BGB324 can increase the effectiveness of immunotherapy.
Poster session details:
Session title: Immune Modulating Agents 1
Session date and time: Sunday, April 17, 2016, 1:00 PM
Location: Convention Center, Halls G-J, Poster Section 26